000538 云南白药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入29,915,1550.76%39,111,29236,488,37336,373,91932,742,767
减:营业总成本25,480,754-0.68%35,082,75032,087,16831,739,81828,425,125
    其中:营业成本21,418,847-0.66%28,744,51826,883,48526,498,43523,655,878
               财务费用(128,382)-32.87%(259,244)(342,878)(258,281)(231,946)
               资产减值损失(14,008)-207.82%(58,128)(664,339)(143,220)(125,480)
公允价值变动收益(18,774)-118.11%123,566(619,903)(1,929,217)2,240,369
投资收益685,143-2.57%779,011868,1981,044,401392,173
    其中:对联营企业和合营企业的投资收益700,9088.07%628,532732,233(21,100)6,308
营业利润5,010,8892.82%4,830,5063,371,2793,485,1696,812,003
利润总额5,013,2513.07%4,818,0123,377,0023,481,6466,801,136
减:所得税费用683,551-7.78%695,451536,593683,9861,290,099
净利润4,329,7005.03%4,122,5612,840,4102,797,6615,511,036
减:非控股权益2,972-406.00%28,779(160,716)(7,256)(5,036)
股东净利润4,326,7284.93%4,093,7823,001,1262,804,9175,516,072

市场价值指针
每股收益 (元) *2.4204.76%2.2901.9002.2104.320
每股派息 (元) *1.213--2.0771.5201.6003.900
每股净资产 (元) *22.7112.31%22.19421.42829.80029.789
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容